(Total Views: 511)
Posted On: 11/22/2021 9:42:53 AM
Post# of 153930
Re: Buddyboy20 #110833
I like this from the article -
Leronlimab can do both.
Quote:
“Based on our observations, there is evidence that an inhibitor of nanotube formation could be combined with cancer immunotherapies and tested to see if it can improve outcomes for patients.”
Leronlimab can do both.
(13)
(0)
